The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery

Recruiting now · Not applicable

Conditions studied: Acute Normovolemic Hemodilution, Bone Tumor, Goal-Directed Fluid Therapy, Transfusion

In brief

The prevention of intraoperative allogenetic blood transfusion has the potential to reduce complications, hospital stays, and long-term prognosis in patients undergoing bone cancer surgery. Data from previous studies suggest that the clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial. The HEAL trial will assess whether ANH will reduce the volume of intraoperative allogeneic red blood cell transfusion in patients undergoing bone cancer surgery.

Key facts

Study ID

NCT06459141

Run by

Second Affiliated Hospital, Zhejiang University, School of Medicine

People needed

150

Starts

2024-06-07

Expected to finish

2028-05-01

Last updated by the study team

2026-06-25

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age 18 to 75 years;
• undergoing elective bone tumor resection surgery;
• preoperative hemoglobin ≥11 g/dL;

You may not qualify if…

• using a tourniquet;
• palliative operation or minimally invasive surgery;
• BMI<18.5 or >30Kg/m\^2;
• international normalized ratio (INR) >1.5 or platelet count <100 × 10\^9/L;
• cardiopulmonary insufficiency;
• hepatic and renal dysfunction;
• active infectious disease;
• allergy to succinyl gelatin;
• pregnancy;
• declined participation in the study or declined blood transfusion

Where it is running

• The Second Affiliated Hospital of Zhejiang University anesthesiology department — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.